https://www.medscape.com/viewarticle/933227
HCQ Trial to Resume
A global randomized controlled trial testing whether the antimalarial drugs hydroxychloroquine and chloroquine can prevent COVID-19 in healthcare workers or other high-risk workers will resume, Reuters reports. The UK Medicines and Healthcare Products Regulatory Agency had paused the COPCOV trial after another British trial found hydroxychloroquine to have no benefit for already-infected COVID-19 patients.
“Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomized controlled trial,” said the trial’s co-leader. “The question whether (it) can prevent COVID-19 or not remains as pertinent as ever.”
Filed under: General Problems
Leave a Reply